Pharma Sector Did Its Job With COVID-19 Vaccine: Barclays Analyst

Loading...
Loading...

The pharmaceutical industry has succeeded in doing its job in manufacturing multiple vaccines for the novel coronavirus, and it's "now in the hands" of government authorities to manage the distribution, Emily Field, head of European pharmaceutical research at Barclays, Emily Field said Friday on CNBC's "Squawk Box Europe."

Price Not A Factor: Early indications suggest AstraZeneca plc AZN and Johnson & Johnson's JNJ vaccine will cost $3 to $5, while pricing for Pfizer Inc. PFE and Moderna Inc MRNA could reach $40 on the high end.

Pricing is unlikely to be a determining factor as governments are prioritizing getting as many people vaccinated as quickly as possible given a limited initial supply, Field said. 

"As long as we know it is safe and efficacious, I don't think that price is going to be a determining factor," she said.

Convincing The Public: The general public should be reminded that results from vaccine trials are "the best we could have hoped for," the Barclays analyst said. 

Public opinion and attitudes toward the vaccine could be impacted by mixed messages from the World Health Organization and the U.S. FDA related to Gilead Sciences, Inc. GILD, she said.

Specifically, the WHO was encouraging doctors worldwide not to use Gilead's remdesivir as a treatment against the coronavirus.

Related Link: Pfizer, BioNTech File First For Emergency Use Authorization Of Coronavirus Vaccine

These public disputes may help skeptics prove their point that the medical community isn't as confident as they appear to be, Field said. 

To counter this argument, it should be noted remdesivir was designed years before the start of the pandemic to treat other viruses such as Ebola, the analyst said.

AstraZeneca was quick to design a new antibody treatment for COVID-19, she said. 

"In essence, these older drugs really weren't meant to treat COVID-19, so it makes sense that there is some debate over their efficacy in treating this disease." 

Loading...
Loading...
date
ticker
name
Price Target
Upside/Downside
Recommendation
Firm
Posted In: Analyst ColorBiotechHealth CareAnalyst RatingsMediaGeneralBarclaysCoronavirusCovid-19Emily Fieldvaccine
We simplify the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.

Join Now: Free!

Loading...